Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$24.8B

May6Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc is a healthcare company focused on acquiring and managing pharmaceutical royalties. With a market cap of $24 billion, it plays a significant role in the pharmaceutical industry by providing funding to biopharmaceutical companies, allowing them to invest in research and development.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$1.18

Revenue

Total revenue shows how well the company is performing in terms of sales, which is critical for assessing growth.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma did not provide specific guidance, leaving investors uncertain about future performance. However, the company has historically struggled to meet earnings expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report earnings of $1.18 per share on revenues of $874 million. The market is cautiously optimistic, given the company's historical challenges.

Bull Case

If the company beats expectations, it could signal improved operational efficiency and growth potential, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations again, it could raise concerns about its long-term viability and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$1.18

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$874M

Total revenue shows how well the company is performing in terms of sales, which is critical for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet or exceed the consensus estimate of $1.18?

This figure is crucial for investor confidence and could significantly impact the stock price.

What insights can management provide regarding revenue growth trends?

Understanding revenue dynamics is essential for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Royalty Pharma to exceed earnings expectations based on historical trends and market conditions.

Supporting Evidence

The company has a history of surprising the market positively despite recent struggles.

Options pricing suggests a significant move is expected, indicating that traders are anticipating volatility.

Key Risk

If the company reports an EPS significantly above $1.18, it could invalidate the cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these earnings as they could indicate whether the company is turning a corner or continuing its historical struggles.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.15 would likely raise concerns about the company's profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

The options market is pricing in a potential move of about 4.5% in either direction, indicating some uncertainty ahead of the earnings report.

Detail

30d HV

21.5%

Calls (400)P/C Ratio: 0.75Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 14 of 30 (47%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 30 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.6%, with a raw directional average of +2.5% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests a potential stock increase of around 5.6%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainties about growth.

Miss

A miss could lead to a significant decline, with historical patterns suggesting an average drop of around 5.6% following disappointing earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Discussion on future revenue growth drivers and pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$1.18

Revenue

Total revenue shows how well the company is performing in terms of sales, which is critical for assessing growth.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report earnings of $1.18 per share on revenues of $874 million. The market is cautiously optimistic, given the company's historical challenges.

Bull Case

If the company beats expectations, it could signal improved operational efficiency and growth potential, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations again, it could raise concerns about its long-term viability and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$1.18

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$874M

Total revenue shows how well the company is performing in terms of sales, which is critical for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS meet or exceed the consensus estimate of $1.18?

This figure is crucial for investor confidence and could significantly impact the stock price.

What insights can management provide regarding revenue growth trends?

Understanding revenue dynamics is essential for assessing the company's future performance and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Royalty Pharma to exceed earnings expectations based on historical trends and market conditions.

Supporting Evidence

The company has a history of surprising the market positively despite recent struggles.

Options pricing suggests a significant move is expected, indicating that traders are anticipating volatility.

Key Risk

If the company reports an EPS significantly above $1.18, it could invalidate the cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these earnings as they could indicate whether the company is turning a corner or continuing its historical struggles.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong operational performance and growth potential.

Bear Confirmed If

An EPS below $1.15 would likely raise concerns about the company's profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±4.5%

The options market is pricing in a potential move of about 4.5% in either direction, indicating some uncertainty ahead of the earnings report.

Detail

30d HV

21.5%

Calls (400)P/C Ratio: 0.75Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 14 of 30 (47%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests a potential stock increase of around 5.6%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainties about growth.

Miss

A miss could lead to a significant decline, with historical patterns suggesting an average drop of around 5.6% following disappointing earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or acquisitions.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Discussion on future revenue growth drivers and pipeline developments.